Jul 15, 2026· Comment from Center for Biological Diversity· FDA-2025-P-5434-0006
Filed as an attachment.
FDANonrulemakingFDA-2025-P-5434
Requests that the FDA revoke its actions to approve the Abbreviate New Drug Application 216616, a generic version of Mifepristone, and modify the associated regimen (including the REMS) until the agency determines that it has complied with the various states’ water quality standards as compelled by the CWA
RIN
—
Last modified
Oct 17, 2025
Comment window
—
Center for Biological Diversity filings
1
Activity
Center for Biological Diversity filed 1 comment on this docket between Jul 15, 2026 and Jul 15, 2026. 1 other organizations filed here.
What Center for Biological Diversity filed (1)
Abstract
Open
View on regulations.gov →Co-filers (1)
See everyone who commented →- Center for Biological DiversityTHIS ORG1 filing · confidence 97%
- Guttmacher Institutetrade assoc.1 filing · confidence 85%